{"id":960406,"date":"2026-05-08T08:05:48","date_gmt":"2026-05-08T12:05:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-reports-first-quarter-2026-financial-results-and-provides-corporate-update\/"},"modified":"2026-05-08T08:05:48","modified_gmt":"2026-05-08T12:05:48","slug":"alx-oncology-reports-first-quarter-2026-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-reports-first-quarter-2026-financial-results-and-provides-corporate-update\/","title":{"rendered":"ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n
\n – Data from Phase 1b\/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination –<\/em>
\n <\/strong>\n <\/p>\n

\n
\n – Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer –<\/em>
\n <\/strong>\n <\/p>\n

\n
\n – Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 –<\/em>
\n <\/strong>\n <\/p>\n

\n
\n – Phase 1 trial evaluating ALX2004 continues to enroll well, on track for safety data in 2H 2026 –<\/em>
\n <\/strong>\n <\/p>\n

\n
\n – ALX strengthens leadership team with the appointment of Jeff Knight as Chief Development and Operating Officer –<\/em>
\n <\/strong>\n <\/p>\n

\n
\n – Company to host webcast including presentation of ESMO Breast data by breast cancer expert <\/em>
\n <\/strong>
\n
\n
\n Sara Hurvitz, M.D., FACP, on <\/em>
\n <\/strong>
\n
\n Friday, May 8, at 5:30 a.m. PT \/ 8:30 a.m. ET –<\/em>
\n <\/strong>\n <\/p>\n

SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (\u201cALX Oncology\u201d Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.<\/p>\n

\u201cWe are encouraged by the data presented yesterday at the ESMO Breast Cancer 2026 congress, which reinforce the potential of our CD47-inhibitor evorpacept to provide durable responses in patients with HER2-positive cancers that express high levels of CD47,\u201d said Jason Lettmann, Chief Executive Officer at ALX Oncology. \u201cCoupled with the previous results from the ASPEN-06 gastric cancer trial, these findings validate our development strategy and reinforce our confidence in the ongoing Phase 2 ASPEN-09-Breast trial. Additionally, we are pleased with the progress of the Phase 1 trial for ALX2004, which remains on track to report dose-escalation safety data this year. With a strengthened balance sheet, we are well-positioned to deliver key data readouts from both ongoing clinical programs.\u201d<\/p>\n

\u201cIt is encouraging to see clinical improvements in patients with heavily pre-treated HER2-positive breast cancer. As the landscape for HER2-positive advanced breast cancer continues to evolve, there remains a clear need for new options once patients\u2019 disease progresses following treatment with currently available therapies, including trastuzumab deruxtecan,\u201d said Sara Hurvitz, M.D., Professor, Senior Vice President and Director, Clinical Research Division and Smith Family Endowed Chair in Women\u2019s Health at Fred Hutchinson Cancer Center, University of Washington. \u201cThe findings from this Phase 1b\/2 trial suggest that combining evorpacept with HER2-targeted agents, guided by CD47 biomarker-driven selection, may offer a promising strategy to address this unmet need.\u201d<\/p>\n

\n ALX Oncology Q1 2026 Highlights and Recent Developments <\/strong>\n <\/p>\n

\n Evorpacept<\/strong>\n <\/p>\n